Full antigenic signature capture
Imvax’s Goldspire™ platform exposes the full antigenic signature of a patient’s tumor to the immune system, providing an opportunity for a broader anti-tumor effect compared with single antigen-targeting therapies.
Informed by decades of research, Imvax’s platform elegantly turns the complexity of a solid tumor against itself by capturing its complete antigenic signature and converting it into a highly immunostimulatory ‘training program’. This is designed to deliver both innate and adaptive immune stimulation to overcome the challenges of solid tumors’ variability and ability to suppress the immune system.
Imvax’s Goldspire™ platform is a personalized, whole tumor-derived, cell-based autologous immunotherapy that delivers a full tumor antigen payload to patients by combining patient-derived tumor cells and an antisense oligodeoxynucleotide (IMV-001) against insulin-like growth factor type 1 receptor (IGF-1R). This combination is loaded into implantable, proprietary biodiffusion chambers (BDCs). Our platform is designed to be incorporated into the standard of care. In the graphic below, click into the two major steps unique to Imvax’s platform to learn more. Click here for a detailed downloadable summary of Goldspire's mechanism.
Imvax’s Goldspire™ platform exposes the full antigenic signature of a patient’s tumor to the immune system, providing an opportunity for a broader anti-tumor effect compared with single antigen-targeting therapies.
Imvax’s Goldspire™ platform delivers immunotherapy that is personalized to a patient’s entire unique tumor and incorporates mechanisms that stimulate both the innate and adaptive immune system. This broad-spectrum effect, when used in combination, also may enhance the effects of other immunotherapies.
Imvax’s Goldspire™ platform trains the immune system to comprehensively recognize the full antigenic signature of a patient’s unique tumor. Because the immune system ignores a patient’s own antigens, Imvax’s approach should avoid immune responses not directed to the tumor itself.
Imvax’s Goldspire™ platform uses a rapid tumor tissue processing technology to prepare the proprietary BDCs for implantation. By contrast, many emerging therapies targeting one or a small number of antigens require complex manufacturing procedures, such as gene editing and cell expansions, that can take several weeks.
Imvax’s Goldspire™ platform can fit within the existing standard of care for patients with resectable solid tumors. Within days of tumor resection surgery, Imvax processes the tumor cells and the BDCs are then implanted in the patient and explanted 48-hours later. The patient’s immune system training begins immediately, after which they can continue with traditional standard-of-care therapies.
Andrews, C.E. et al. “Targeted immunotherapy for glioblastoma involving whole tumor-derived autologous cells in the upfront setting after craniotomy.” Journal of Neuro-Oncology, Nov. 2023. DOI 10.1007/s11060-023-04491-4
Lee, I. et al. “Autologous cell immunotherapy (IGV-001) with IGF-1R antisense oligonucleotide in newly diagnosed glioblastoma patients.” Future Medicine, Dec. 2023. DOI 10.2217/fon-2023-0702
Perez-Olle, R. et al. “Additional Results From a Phase 1b Study of IGV-001 in Patients With Newly Diagnosed Glioblastoma” Presented at SNO 2023.